Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
The guidelines are the result of a consensus of an international task force of MG experts.
Treatment has been linked to durable, symptom-free, treatment-free remission in several cases of MG.
Neurology Advisor Articles
- Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence
- Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease
- MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics
- Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability
- The Handoff: Your Week in Neurology News - 9/21/17
- Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease
- Cognitive Decline Related to Site Specific Mid-Life Adiposity
- Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline
- Higher Doses of Pregabalin for Neuropathic Pain: Is it Safe?
- Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus
- Zika Virus Associated With High Risk for Neurologic Complications in Adults
- Evolocumab Has No Effect on Cognition in Patients Attaining Very Low Levels of LDL Cholesterol
- Acute Oxygen Therapy for Cluster Headahce Not Prohibitively Expensive
- β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD
- Little Evidence to Support Doctor, Patient Electronic Communication Guidelines